Navigation Links
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Date:9/11/2012

MADISON, Wis., Sept. 11, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the second cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.  The second two-patient cohort was successfully dosed with approximately 40 mCi of HOT, triggering enrollment into the third cohort at approximately 60 mCi.  Details of the trial design are available on www.clinicaltrials.gov ID: NCT01495663, or at www.novelos.com in the 'Clinical Trials' section.  Glenn Liu, M.D., Associate Professor of Medicine and Director of the Cancer Therapy Discovery and Development (Phase I) Program at the University of Wisconsin Carbone Cancer Center, is the trial's principal investigator.  Detailed trial results are expected to be presented at a scientific venue at a later date.

"Data from this second cohort indicates that HOT was well-tolerated, without any dose-limiting or sub-dose-limiting toxicities, enabling enrollment of the third cohort as planned," said Dr. Liu.  "We continue to observe selective uptake of HOT in cancerous tumors where it persists for at least 21 days."

"We are pleased with HOT's safety profile and selective cancerous tumor uptake and retention in this second cohort at a dose of approximately 40 mCi," said Kim Hawkins, Vice President of Clinical Development of Novelos.  "We now look forward to evaluating HOT at approximately 60 mCi in cancer patients with advanced solid tumors, as per the trial protocol."

"We expect to begin HOT Phase 2 proof-of-concept trials in the third quarter of 2013 in cancer patients that have significant unmet medical need," said Harry
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
7. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... ATLANTA , August 27, 2015 ... Consortium convened in Boston on ... Consortium in an effort to more fully exploit the ... are applied to brain diseases. "As an ... has a responsibility to assume a leadership role - ...
(Date:8/27/2015)... FRANCISCO, Calif. , Aug. 27, 2015 /PRNewswire/ ... therapeutics for the treatment of cancer, today announced ... member of the company,s Board of Directors, has ... led immuno-oncology at Eli Lilly and AstraZeneca, and ... first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
(Date:8/27/2015)... , ... August 27, 2015 , ... ... average annual cost to treat a patient with hemophilia is $175,000. Hemophilia is ... a cure and improving treatment. The RMHBDA exists to help raise funds for ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... According ... and the American Heart Association have released new guidelines to educate doctors and patients ... last update to these particular guidelines came in 2007, so the new version is ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), part ... medical centers in the United States to receive international recognition for an advanced, ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions dedicated ...
(Date:8/27/2015)... ... , ... About 10 percent of mothers experienced chronic, persistent ... more than 1,800 people, displacing hundreds of thousands and causing widespread damage estimated ... While most people don’t develop persistent depression after a major disaster like that, ...
(Date:8/27/2015)... Hills, CA (PRWEB) , ... August 27, 2015 ... ... Wearables & IoT Summit , scheduled for October 27-29, 2015 in San Jose, ... technology, the summit will primarily focus on the void that exists where battery ...
Breaking Medicine News(10 mins):Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2
... of Women,s ... Ovarian Reserve, COLORADO ... announced it will be the first IVF center,in the region to ... an assessment of a woman,s egg supply by combining,multiple factors including ...
... claims companies knowingly misled consumers on the use of Zetia and ... ... Hagens Berman Sobol Shapiro filed,a proposed class-action lawsuit against Merck (NYSE: ... Vytorin alleging,Merck and Schering-Plough violated state consumer protection laws arising,from the sale ...
... Inc. (TSX: DDS,NASDAQ: DDSS) today announced that it ... iNova Pharmaceuticals (Australia) Pty Limited,for its once-daily tramadol ... of our once-daily tramadol product across,Europe and in ... as we,prepare for additional product launches in key ...
... 24 Weight Watchers,International, Inc. (NYSE: WTW ) ... year 2007 after the NYSE close on Thursday, February ... call on February 14th at,5:00 p.m. ET. During the ... Ann Sardini, Chief Financial Officer, will,discuss fourth quarter and ...
... with a camera could detect the earliest signs of cancer? ... in confined spaces. Such a device could find warning signs ... States. , A fundamentally new design has created a smaller ... to use than current technology. Its first use on a ...
... published today in the February issue of the ... of Biomaterials, Dalhousie University (Halifax, NS, Canada), and ... on Dentistry, denounces new Norwegian regulations governing the ... use of dental amalgam not only in Norway, ...
Cached Medicine News:Health News:Reproductive Medicine & Fertility Center is First in Southwest to Offer Pioneering Test of a Women's Biological Clock 2Health News:Reproductive Medicine & Fertility Center is First in Southwest to Offer Pioneering Test of a Women's Biological Clock 3Health News:Reproductive Medicine & Fertility Center is First in Southwest to Offer Pioneering Test of a Women's Biological Clock 4Health News:CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough 2Health News:CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough 3Health News:Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova 2Health News:Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova 3Health News:Weight Watchers Announces Fourth Quarter and Full Year 2007 Earnings Conference Call 2Health News:Camera in a pill offers cheaper, easier window on your insides 2Health News:Camera in a pill offers cheaper, easier window on your insides 3Health News:Materials expert denounces Norwegian ban on dental amalgam 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: